Last reviewed · How we verify
rAAV1.CMV.huFollistin344
rAAV1.CMV.huFollistin344 is a Biologic drug developed by Jerry R. Mendell. It is currently in Phase 1 development.
At a glance
| Generic name | rAAV1.CMV.huFollistin344 |
|---|---|
| Sponsor | Jerry R. Mendell |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystrophy (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rAAV1.CMV.huFollistin344 CI brief — competitive landscape report
- rAAV1.CMV.huFollistin344 updates RSS · CI watch RSS
- Jerry R. Mendell portfolio CI
Frequently asked questions about rAAV1.CMV.huFollistin344
What is rAAV1.CMV.huFollistin344?
rAAV1.CMV.huFollistin344 is a Biologic drug developed by Jerry R. Mendell.
Who makes rAAV1.CMV.huFollistin344?
rAAV1.CMV.huFollistin344 is developed by Jerry R. Mendell (see full Jerry R. Mendell pipeline at /company/jerry-r-mendell).
What development phase is rAAV1.CMV.huFollistin344 in?
rAAV1.CMV.huFollistin344 is in Phase 1.
Related
- Manufacturer: Jerry R. Mendell — full pipeline
- Compare: rAAV1.CMV.huFollistin344 vs similar drugs
- Pricing: rAAV1.CMV.huFollistin344 cost, discount & access